About this Research Topic
Diabetes mellitus (DM) is a clinical condition characterized by altered glucose homeostasis. The main characteristic of type 1 DM is a reduction in the mass of pancreatic beta cells, whereas an alteration in their function, associated with a state of insulin resistance, is the main feature of type 2 DM. The link between diabetes and transplants includes the metabolic alterations that arise after a solid organ transplant (the relative β-cell deficiency that is secondary to the use of immunosuppressive therapy), as well as β-cell replacement therapy. In fact, the only treatments that can ensure the normalization of blood glucose without exogenous insulin administration are pancreas transplantation and pancreatic islet transplantation. Furthermore, research and technologies are constantly evolving for the use of cell therapy for diabetes (e.g., adult or pluripotent stem cells) in the field of regenerative medicine.
This Research Topic focuses on all aspects of diabetes and transplantation. It aims to meet the need to enhance evidence on the pathogenetic/ therapeutic pathways of metabolic alterations secondary to solid organ transplantation, as well as evidence on innovative therapies for the treatment of diabetes relating to transplants and regenerative medicine.
Specific themes of interest include, but are not limited to:
- Epidemiological aspects of post-transplant metabolic alterations
——评估移植结果有关pre-existing and newly diagnosed metabolic alterations (e.g., obesity, diabetes, metabolic fatty liver disease and steatohepatitis)
- Pathogenetic mechanisms involved in the metabolic diseases secondary to immunosuppressive therapy
- Safety and efficacy of new antidiabetic treatments in post-transplant diabetes
- Clinical management and outcomes of pancreas transplantation, combined kidney-pancreas transplantation, and pancreatic islet transplantation
- Re-occurrence of diabetes after beta-cell replacement therapy
- Impact of beta cell replacement therapy on diabetes-related complications
- Regenerative medicine and organ engineering, including stem cell-based treatment for diabetes remission and care
- Clinical uses of regenerative medicine for the treatment of diabetes-related complications (arteriopathy, retinopathy, nephropathy)
All article types accepted by Frontiers are encouraged.
This Research Topic focuses on all aspects of diabetes and transplantation. It aims to meet the need to enhance evidence on the pathogenetic/ therapeutic pathways of metabolic alterations secondary to solid organ transplantation, as well as evidence on innovative therapies for the treatment of diabetes relating to transplants and regenerative medicine.
Specific themes of interest include, but are not limited to:
- Epidemiological aspects of post-transplant metabolic alterations
——评估移植结果有关pre-existing and newly diagnosed metabolic alterations (e.g., obesity, diabetes, metabolic fatty liver disease and steatohepatitis)
- Pathogenetic mechanisms involved in the metabolic diseases secondary to immunosuppressive therapy
- Safety and efficacy of new antidiabetic treatments in post-transplant diabetes
- Clinical management and outcomes of pancreas transplantation, combined kidney-pancreas transplantation, and pancreatic islet transplantation
- Re-occurrence of diabetes after beta-cell replacement therapy
- Impact of beta cell replacement therapy on diabetes-related complications
- Regenerative medicine and organ engineering, including stem cell-based treatment for diabetes remission and care
- Clinical uses of regenerative medicine for the treatment of diabetes-related complications (arteriopathy, retinopathy, nephropathy)
All article types accepted by Frontiers are encouraged.
Keywords: Diabetes mellitus, Transplantation, Post-transplant Diabetes Mellitus, Beta-cell replacement therapy, Pancreas transplantation, Islet transplantation, Stem cell-based therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
